Clik here to view.
ONCODESIGN: 1st Half of 2014
DIJON, France ONCODESIGN, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known...
View ArticleClik here to view.
Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal...
CAMBRIDGE, England Biosceptre, the oncology company developing antibody products that target the nf-P2X7 receptor, announces positive results from its Phase I trial to assess the safety and...
View ArticleClik here to view.
Dr. Reddy’s to Release Q1 FY15 Results on July 30, 2014
HYDERABAD, India Dr. Reddy’s Laboratories (NYSE: RDY) will announce results for the First Quarter ended June 30, 2014 on Wednesday, July 30, 2014 after the Board Meeting. The results will be...
View ArticleClik here to view.
エリテック、米国にて急性リンパ芽球性白血病を対象に ERY-ASPを検討する第 I/II 相試験で、初の患者組み入れを発表
仏リヨン （ビジネスワイヤ） — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的な「腫瘍飢餓化」治療薬の開発に当たっているフランスのバイオ製薬企業エリテック・ファーマ（Paris:ERYP）（Euronext Paris: FR0011471135 – ERYP）は、米国にて急性リンパ芽球性白血病を対象に ERY-ASPを検討する第 I/II...
View ArticleClik here to view.
Personalized Chemotherapy Tests Cleared for Use in China
SHANGHAI & BETHLEHEM, Pa. Fosun Diagnostics, a division of Fosun Pharmaceuticals, and Saladax Biomedical, Inc. today announced the launch of the MyCare™ portfolio of exposure optimization tests...
View ArticleClik here to view.
Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce Strategic...
NEW YORK & OSAKA, Japan Bristol-Myers Squibb Company (NYSE:BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) have signed a strategic collaboration agreement to jointly develop and commercialize...
View ArticleClik here to view.
CANbridge Life Sciences And EUSA Pharma Form Agreement to Commericalize...
BEIJING CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has entered into an exclusive partnership with EUSA Pharma, a Jazz...
View ArticleClik here to view.
ERYTECH Announces Enrollment of First Patient in Phase II Study of ERY-ASP in...
LYON, France Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 – ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute...
View ArticleClik here to view.
エリテックがすい臓がんでERY-ASPを検討する第II相試験で最初の患者組み入れを発表
仏リヨン （ビジネスワイヤ） — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的な「腫瘍飢餓化」治療薬の開発に当たっているフランスのバイオ製薬企業エリテック・ファーマ（Paris:ERYP）（Euronext Paris: FR0011471135 –...
View ArticleClik here to view.
Dr. Reddy’s Q1 FY15 Financial Results
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced its unaudited consolidated financial results for the quarter ended June 30, 2014 under International Financial Reporting...
View ArticleClik here to view.
Kapa Biosystems Strengthens Investment across Asia Pacific Region by...
WILMINGTON, Mass. Kapa Biosystems announced today that it has signed a new three-year exclusive distribution agreement with Nippon Genetics Co., Ltd., further extending the successful seven-year...
View ArticleClik here to view.
NanoString Technologies Receives Market Approval From the Australian...
SEATTLE NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and developer of molecular diagnostic products, today announced that it has received...
View ArticleClik here to view.
ZRG Partners Life Sciences Hiring Index Q2 Declines Slightly but Still Near...
WEST ORANGE, N.J. ZRG Partners, Inc. announces the results of its second quarter Global Life Sciences Hiring Index. Q2 displays a slightly negative turn but the overall outlook remains positive with...
View ArticleClik here to view.
CANCER RESEARCH UK AND CANCER RESEARCH TECHNOLOGY JOIN FORCES WITH ASTELLAS...
LONDON Cancer Research UK and its commercial arm, Cancer Research Technology (“CRT”), are to join forces with Astellas Pharma Inc. (Tokyo, President & CEO: Yoshihiko Hatanaka, “Astellas”) to...
View ArticleClik here to view.
FDA Approves VELCADE® (bortezomib) Retreatment in Patients with Multiple Myeloma
CAMBRIDGE, Mass. Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the U.S. Food and Drug Administration (FDA)...
View ArticleClik here to view.
Provectus Signs Memorandum of Understanding with Sinopharm-China State...
KNOXVILLE, Tenn. Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that...
View ArticleClik here to view.
Provectus 与国药-中国医药工业研究总院和 国药A-THINK Pharmaceuticals Co., Ltd.签署谅解备忘录
田纳西州诺克斯维尔 (美国商业资讯) — Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com)是一家开发阶段肿瘤科和皮肤科生物制药公司(“Provectus”)。公司今天宣布已与国药-中国医药工业研究总院（国药-CSIPI，中国所有医药研究院中的领先者）和国药 A-THINK...
View ArticleClik here to view.
Clik here to view.
Clik here to view.